scholarly journals A Vesicular Stomatitis Virus-Based Therapeutic Vaccine Generates a Functional CD8 T Cell Response to Hepatitis B Virus in Transgenic Mice

2012 ◽  
Vol 87 (5) ◽  
pp. 2969-2973 ◽  
Author(s):  
M. A. Cobleigh ◽  
X. Wei ◽  
M. D. Robek
2010 ◽  
Vol 84 (15) ◽  
pp. 7513-7522 ◽  
Author(s):  
Melissa A. Cobleigh ◽  
Linda Buonocore ◽  
Susan L. Uprichard ◽  
John K. Rose ◽  
Michael D. Robek

ABSTRACT As one of the world's most common infectious diseases, hepatitis B virus (HBV) is a serious worldwide public health problem, with HBV-associated liver disease accounting for more than half a million deaths each year. Although there is an effective prophylactic vaccine currently available to prevent infection, it has a number of characteristics that are suboptimal: multiple doses are needed to induce long-lasting immunity, immunity declines over time, it does not elicit protection in some individuals, and it is not effective therapeutically. We produced a recombinant vesicular stomatitis virus (VSV)-based vaccine vector expressing the HBV middle envelope surface protein (MS) and found that this vector was able to efficiently generate a strong HBs-specific antibody response following a single immunization in mice. A single immunization with the VSV-MS vector also induced robust CD8 T-cell activation. The CD8 T-cell response was greater in magnitude and broader in specificity than the response generated by a vaccinia virus-based vaccine vector or by recombinant protein immunization. Furthermore, a single VSV-MS immunization provided protection against virus challenge in mice. Given the similar antibody titers and superior T-cell responses elicited from a single immunization, a VSV-based HBV vaccine may have advantages over the current recombinant protein vaccine.


AIDS ◽  
2012 ◽  
Vol 26 (17) ◽  
pp. 2145-2153 ◽  
Author(s):  
Guangxu Ren ◽  
Stefan Esser ◽  
Christoph Jochum ◽  
Joerg F. Schlaak ◽  
Guido Gerken ◽  
...  

AIDS ◽  
2004 ◽  
Vol 18 (12) ◽  
pp. 1734-1737 ◽  
Author(s):  
Theo Gouskos ◽  
Fiona Wightman ◽  
Judy Chang ◽  
Linda Earnest-Silveira ◽  
Joseph Sasadeusz ◽  
...  

2018 ◽  
Vol 9 ◽  
Author(s):  
Sheila F. Lumley ◽  
Anna L. McNaughton ◽  
Paul Klenerman ◽  
Katrina A. Lythgoe ◽  
Philippa C. Matthews

2009 ◽  
Vol 83 (19) ◽  
pp. 9652-9662 ◽  
Author(s):  
Shinichi Asabe ◽  
Stefan F. Wieland ◽  
Pratip K. Chattopadhyay ◽  
Mario Roederer ◽  
Ronald E. Engle ◽  
...  

ABSTRACT The impact of virus dose on the outcome of infection is poorly understood. In this study we show that, for hepatitis B virus (HBV), the size of the inoculum contributes to the kinetics of viral spread and immunological priming, which then determine the outcome of infection. Adult chimpanzees were infected with a serially diluted monoclonal HBV inoculum. Unexpectedly, despite vastly different viral kinetics, both high-dose inocula (1010 genome equivalents [GE] per animal) and low-dose inocula (10° GE per animal) primed the CD4 T-cell response after logarithmic spread was detectable, allowing infection of 100% of hepatocytes and requiring prolonged immunopathology before clearance occurred. In contrast, intermediate (107 and 104 GE) inocula primed the T-cell response before detectable logarithmic spread and were abruptly terminated with minimal immunopathology before 0.1% of hepatocytes were infected. Surprisingly, a dosage of 101 GE primed the T-cell response after all hepatocytes were infected and caused either prolonged or persistent infection with severe immunopathology. Finally, CD4 T-cell depletion before inoculation of a normally rapidly controlled inoculum precluded T-cell priming and caused persistent infection with minimal immunopathology. These results suggest that the relationship between the kinetics of viral spread and CD4 T-cell priming determines the outcome of HBV infection.


Sign in / Sign up

Export Citation Format

Share Document